acquisition is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Biogen, the most common co-covered peer. Each carries 4 original sources on average. We currently track 1 Healthcare story that mention Indivior Pharmaceuticals, all published on August 4, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Indivior Pharmaceuticals
acquisition is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Biogen, the most common co-covered peer. Each carries 4 original sources on average. We currently track 1 Healthcare story that mention Indivior Pharmaceuticals, all published on August 4, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Indivior Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Supernus Pharmaceuticals is acquiring Indivior in an all-stock deal, assembling a portfolio of 11 FDA-approved CNS treatments. The merger targets $125 million in annual cost synergies and expands the company's footprint in neurology, addiction, and psychiatry. Meanwhile, Q2 revenue jumped 32% to $219 million, but a surprise net loss of $58.1 million casts a shadow over short-term integration risks.
